NEW YORK, NY--(Marketwired - Sep 16, 2015) - Event Cardio Group, Inc. (
"We are extremely pleased to have Julie, a luminary in the breast cancer awareness and media world, join our board and agree to actively serve as the CEO of our BreastCare Division," said John Bentivoglio, Chairman and CEO of Event Cardio Group. "Julie has been at the forefront of the early detection of Breast and other cancers for many years and we believe her first hand experiences in the field have paved the way for companies like Event Cardio Group to introduce medical technology advances. With an impressive list of accomplishments in law, management and business development, Julie will be a terrific addition to our board and a great CEO. We look forward to her contributions as we move forward with our media outreach and marketing efforts to create awareness among women of our noninvasive option for early detection of breast cancer using our BreastCare DTS ® technology."
Ms. Singleton currently divides her time between advisory work in the medical device industry, breast care media outreach and other business interests. She currently serves as Chief Executive Officer of MedPac Asia Pacific PTY Ltd, of Australia, exclusive SouthEast Asia Distributor of BreastCare DTS ® and NowCardio. Ms. Singleton is a lawyer in Australia. Julie is accredited and registered as a Family Dispute Resolution Mediator with the National Accreditation Mediation System and as a Commercial Dispute Mediator. Ms. Singleton serves as an Ambassador for the Australian Gynecological Cancer Foundation and on the Fundraising and Advisory Committee for Family Planning of New South Wales.
"This is an especially exciting time in the commercialization of Event Cardio Group's products," stated Ms. Singleton. "I look forward to working with the Event Cardio Group team to commercialize our innovative medical devices for early detection of high-risk diseases such as heart disease and breast cancer."
About Event Cardio Group, Inc.
Event Cardio Group, Inc. is a developer of medical diagnostic detection equipment focused on detection and preventative treatment of high-risk diseases. The Company's core products are Now Cardio™, an advanced cardiac monitor which offers dual-functionality including both holter monitoring and event recording simultaneously, and its FDA approved BreastCare DTS™ breast cancer detection device. For more information on the Company please visit www.eventcardiogroup.com.
Statements in this release may be regarded, in certain instances, as "forward-looking statements" pursuant to certain sections of the Securities Act 1933 and the Securities Exchange Act 1934, respectively. "Forward-looking statements" are based on expectations, estimates and projections at the time the statements are made, and involve risks and uncertainties, which could cause actual results or events to differ materially from those currently anticipated, including, but not limited to delays, difficulties, changed strategies, or unanticipated factors or circumstances affecting Event Cardio Group, Inc. and its business. There can be no assurance that such forward-looking statements will ever prove to be accurate and readers should not place undue reliance on any such forward-looking statements contained herein. Event Cardio Group, Inc. will not republish revised forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events.